Exsure develops a patented exosomal drug-delivery platform designed to target cancer and cancer-stem cells to reduce chemotherapy toxicity and lower relapse risk. The company also sells in-house R&D reagents including Exosure (3-in-1 exosome isolation reagent), Leucosure (PBMC isolation reagent), PlantExosure (India’s first plant exosome isolation reagent) and Dr Berries. In the last 12 months Exsure initiated a non-clinical study in India with a CRO and completed a milestone in its preclinical work. The company is on track to service more than 50 clients this year with its R&D products. In the coming 12 months it plans to finish the non-clinical study, present data for CDSCO approval, and focus on team building and global marketing and sales expansion. It was also selected for the OIST Innovation Accelerator program in Japan to support business expansion and conducting clinical trials. Exsure raised Rs 3 Cr in a seed funding round to support completion of its non-clinical study and global expansion of its in-house products.

Total raised

$0M

Funding rounds

1

Latest round

Seed

Latest activity

Jan 2025